Skip to main content

Table 5 Clinical features analysed for the patients receiving carbapenem or other AIT between day > 0 and day 30

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 

Missing data

Carbapenems n = 202

Other AIT n = 364

p value

Severity criteria on admission

 SOFA score, median [IQR]

4/8

5 [3–7]

5 [3–6]

NS

 Respiratory failure*, n (%)

0

74 (37)

123 (34)

NS

 Cardiovascular failure*, n (%)

0

79 (39)

118 (32)

NS

 Renal failure*, n (%)

0

39 (19)

77 (21)

NS

 Septic shock, n (%)

0

45 (22)

65 (18)

NS

 Acute respiratory distress syndrome, n (%)

0

27 (13)

25 (7)

< 0.05

Main treatments between day > 0 and day 30

 Need for red blood cell transfusion, n (%)

0

87 (43)

104 (29)

< 0.001

 Number of days of mechanical ventilation

5/5

12 [2–26]

2 [0–10]

< 0.001

 Vasoactive support, n (%)

0/1

147 (73)

184 (51)

< 0.001

 Renal replacement therapy, n (%)

0/1

82 (41)

94 (26)

< 0.001

 Duration of RRT, days, median [IQR]

6/5

10 [3–22]

5 [2–13]

< 0.01

Main complications between day > 0 and day 30

 Acute respiratory distress syndrome, n (%)

1/1

101 (50)

100 (28)

< 0.001

 Septic shock, n (%)

15/31

102 (55)

106 (32)

< 0.001

 Pancreatic necrosis, n (%)

4/14

156 (79)

229 (65)

< 0.001

 Infected necrosis, n (%)

8/20

96 (49)

100 (29)

< 0.001

 Gastro-intestinal perforation, n (%)

12/18

23 (12)

27 (8)

NS

 Vascular thrombosis, n (%)

9/16

36 (19)

47 (14)

NS

 Acute mesenteric ischaemia, n (%)

10/17

26 (14)

36 (10)

NS

 Intra-abdominal collection, n (%)

6/15

105 (54)

131 (38)

< 0.001

 Abdominal compartment syndrome, n (%)

9/17

33 (17)

32 (9)

< 0.01

 Haemorrhage, n (%)

8/18

44 (23)

35 (10)

< 0.001

 Peritonitis, n (%)

11/19

36 (19)

47 (14)

NS

 Cholangitis, n (%)

8/17

18 (9)

39 (11)

NS

 Digestive fistula, n (%)

10/18

11 (6)

19 (5)

NS

Clinical management between day > 0 and day 30

 Endoscopic necrosectomy, n (%)

1/5

76 (38)

71 (20)

< 0.001

 Surgical necrosectomy, n (%)

1/5

94 (47)

123 (34)

< 0.01

 Radiological drainage, n (%)

1/5

63 (31)

56 (16)

< 0.001

 Main reasons for anti-infective therapy between day > 0 and day 30

 Intra-abdominal infection, n (%)

11/13

153 (80)

194 (55)

< 0.001

 Pneumonia, n (%)

11/14

79 (41)

89 (25)

< 0.001

 Bacteraemia, n (%)

10/15

60 (31)

76 (22)

< 0.05

Anti-infective therapy administered between day > 0 and day 30

 Duration of AIT, days, median [IQR]

8/16

10 [3–17]

5 [2–10]

< 0.001

 Aminoglycosides, n (%)

4/19

129 (65)

118 (34)

< 0.001

 Anti-Gram-positive agents, n (%)

10/23

101 (53)

60 (18)

< 0.001

 Antifungal agents, n (%)

0/2

54 (27)

56 (15)

< 0.01

 Azoles, n (%)

6/2

32 (16)

35 (10)

< 0.05

 Echinocandins, n (%)

6/2

24 (12)

20 (6)

< 0.01

Duration of ICU stay, days, median [IQR]

0

22 [9–39]

8 [3–19]

< 0.001

ICU readmission n (%)

1/0

21 (10)

29 (8)

NS

Hospital mortality rate, n (%)

0

64 (32)

77 (21)

< 0.01

Time to death, days, median [IQR]

0

29 [11–45]

4 [1–18]

< 0.001

  1. NS non-significant, NA not applicable, ERCP endoscopic retrograde cholangiopancreatography
  2. *According to the definition of the SOFA score